Related Experiment Video
Updated: Mar 19, 2026
Software-Assisted Quantitative Measurement of Osteoarthritic Subchondral Bone Thickness
Published on: March 18, 2022
Inhibition of SDF-1α/CXCR4 Signalling in Subchondral Bone Attenuates Post-Traumatic Osteoarthritis
Yonghui Dong1, Hui Liu2, Xuejun Zhang3
1Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan 430030, China. dongyonghuitjmu@gmail.com.
Abstract:
Previous studies showed that SDF-1α is a catabolic factor that can infiltrate cartilage, decrease proteoglycan content, and increase MMP-13 activity. Inhibiting the SDF-1α/CXCR4 signalling pathway can attenuate the pathogenesis of osteoarthritis (OA). Recent studies have also shown that SDF-1α enhances chondrocyte proliferation and maturation. These results appear to be contradictory. In the current study, we used a destabilisation OA animal model to investigate the effects of SDF-1α/CXCR4 signalling in the tibial subchondral bone and the OA pathological process. Post-traumatic osteoarthritis (PTOA) mice models were prepared by transecting the anterior cruciate ligament (ACLT), or a sham surgery was performed, in a total of 30 mice. Mice were treated with phosphate buffer saline (PBS) or AMD3100 (an inhibitor of CXCR4) and sacrificed at 30 days post ACLT or sham surgery. Tibial subchondral bone status was quantified by micro-computed tomography (μCT). Knee-joint histology was analysed to examine the articular cartilage and joint degeneration. The levels of SDF-1α and collagen type I c-telopeptidefragments (CTX-I) were quantified by ELISA. Bone marrow mononuclear cells (BMMCs) were used to clarify the effects of SDF-1α on osteoclast formation and activity in vivo. μCT analysis revealed significant loss of trabecular bone from tibial subchondral bone post-ACLT, which was effectively prevented by AMD3100. AMD3100 could partially prevent bone loss and articular cartilage degeneration. Serum biomarkers revealed an increase in SDF-1α and bone resorption, which were also reduced by AMD3100. SDF-1α can promote osteoclast formation and the expression oftartrate resistant acid phosphatase (TRAP), cathepsin K (CK), and matrix metalloproteinase (MMP)-9 in osteoclasts by activating the MAPK pathway, including ERK and p38, but not JNK. In conclusion, inhibition of SDF-1α/CXCR4signalling was able to prevent trabecular bone loss and attenuated cartilage degeneration in PTOA mice.
Insights
Inhibiting the SDF-1α/CXCR4 pathway prevents bone loss and cartilage damage in post-traumatic osteoarthritis (PTOA) models. This study clarifies SDF-1α
Area of Science:
- Orthopedics and Rheumatology
- Cell Biology and Signaling
- Biomedical Engineering
Background:
- Stromal cell-derived factor-1 alpha (SDF-1α) has contradictory roles in osteoarthritis (OA) pathogenesis, acting as both a catabolic factor and promoting chondrocyte proliferation.
- The SDF-1α/CXCR4 signaling pathway's role in post-traumatic osteoarthritis (PTOA), particularly in subchondral bone, requires further investigation.
- Understanding these dual roles is crucial for developing targeted OA therapies.
Purpose of the Study:
- To investigate the effects of SDF-1α/CXCR4 signaling on tibial subchondral bone and articular cartilage in a murine PTOA model.
- To evaluate the therapeutic potential of inhibiting the SDF-1α/CXCR4 pathway using AMD3100.
Main Methods:
- Established a PTOA mouse model via anterior cruciate ligament transection (ACLT).
- Treated mice with phosphate-buffered saline (PBS) or the CXCR4 inhibitor AMD3100.
- Assessed subchondral bone structure using micro-computed tomography (μCT), analyzed knee joint histology, and quantified serum biomarkers (SDF-1α, CTX-I) via ELISA. Evaluated osteoclastogenesis in vitro.
Main Results:
- ACLT induced significant trabecular bone loss in the tibial subchondral bone, which AMD3100 treatment effectively prevented.
- AMD3100 partially mitigated articular cartilage degeneration and reduced elevated serum levels of SDF-1α and bone resorption markers.
- SDF-1α promoted osteoclast formation and activity via MAPK pathway activation (ERK, p38).
Conclusions:
- Inhibition of the SDF-1α/CXCR4 signaling pathway effectively prevents subchondral bone loss in PTOA.
- Targeting SDF-1α/CXCR4 signaling attenuates cartilage degeneration in PTOA.
- These findings highlight the SDF-1α/CXCR4 pathway as a potential therapeutic target for PTOA.
